Physician profile
Collin Curry
NPI 1487269957
$582.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $54.24.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $102.36 | 2021 | |
| Amgen INC. | $97.20 | 2021 | |
| Abbvie INC. | $63.88 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $44.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $43.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.98 | 2021 | |
| Biogen, INC. | $34.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.73 | 2022 | |
| Lilly USA, LLC | $28.87 | 2021 | |
| Ucb, INC. | $22.02 | 2021 | |
| Allergan, INC. | $21.03 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.57 | 2021 | |
| Banner Life Sciences, LLC | $17.52 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.